Health Alert:

NEW VISITOR POLICY in effect as of Friday, March 27
See all Novel Coronavirus Information for Penn Medicine Patients

Cutaneous lymphoma is cancer of the lymphocytes or white blood cells that primarily affect the skin. Lymphocytes help fight infection and are categorized as B-lymphocytes (B-cell) which produce antibodies and T-lymphocytes (T-cell) which regulate the immune system and fight viral infections.  The two major types of lymphoma are Hodgkin disease and non-Hodgkin lymphoma.

Expert Care for Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a rare and typically slow growing type of non-Hodgkin lymphoma. It may initially look like common skin disorders such as eczema, psoriasis or chronic dermatitis. There are many forms of cutaneous T-cell lymphoma, but mycosis fungoides, characterized by patches, plaques and tumors, is the most common type, while Sezary syndrome is less common.

The Cutaneous T-Cell Lymphoma Clinic at Penn Dermatology specializes in diagnosing and treating patients with various forms of cutaneous T-cell lymphoma. The clinic manages and cares for patients across the Philadelphia region and from neighboring states. In the United States, approximately 3,000 new cases of cutaneous T-cell lymphoma are diagnosed annually.

The Penn Dermatology Cutaneous T-Cell Lymphoma Clinic has the largest referral program in the nation. Penn dermatologists routinely evaluate more than 400 new patients per year and manage more than 2,000 outpatients diagnosed with cutaneous T-cell lymphoma annually. In addition, Penn's dermatologists and oncologists work collaboratively to provide comprehensive care.

Dermatology Research Studies and Clinical Trials in Philadelphia

The Penn Cutaneous Lymphoma Program has a long history of research funded by the National Institutes of Health to support the development of new drugs and new treatment protocols. Within the last 25 years, the members of this program have been national leaders as participants in numerous clinical trials testing the effectiveness of new medications and protocols. Penn’s multimodality therapeutic approach to Sezary syndrome has produced transformational results in regard to long term clinical responses.

Patients undergoing treatment at Penn Dermatology may be eligible to participate in several active clinical trials of new drugs on a volunteer basis.

In This Section

Treatments and Procedures

Depending on the progression of Cutaneous T Cell Lymphoma, Penn Dermatology provides cutting-edge treatment options.

Treatment Teams

Penn's world renowned Dermatologists provide expert treatment for Cutaneous T Cell Lymphoma. Browse our list of physicians.

Share This Page: